Date | Title | Description |
18.09.2024 | Patents for software and genetic code could be revived by two bills in Congress | Enlarge / An image from the U.S. Patent and Trademark Office, where in 1874, the newest thing was not software or genetic compositions, but shutter fastenings from H.L. Norton.
Andrew Harrer/Bloomberg via Getty Images reader comments 96
The... |
06.08.2024 | Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% | Highlights
Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).
Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second ... |
06.08.2024 | Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% | Highlights
Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).
Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second ... |
02.07.2024 | Myriad Genetics Earns 2024 Great Place To Work® Certification™ | SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. ... |
02.07.2024 | Myriad Genetics Earns 2024 Great Place To Work® Certification™ | SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. ... |
17.06.2024 | Companion Diagnostics Market Size to Reach $13.74 Billion by 2030: Latest Report by Vantage Market Research | According to a market research study published by Vantage Market Research, the demand analysis of Global Companion Diagnostics Market size revenue was valued at approximately $5.59 Bn in 2022 and is expected to reach around $13.74 Bn by 203... |
23.05.2024 | Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting | Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in gene... |
06.05.2024 | Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024 | Researchers Used Komodo’s Healthcare Map to Uncover Insights Across Oncology, Women’s Health, Mental Health, Neurology, and more
Komodo Insights Power Three Studies Named Finalists for ISPOR 2024 Research Presentation Awards
SAN FRANCISCO &... |
02.05.2024 | YourBio Health Congratulates Myriad Genetics on One Million Sales of SneakPeek® Tests Enabled by YourBio's Virtually Painless TAP Technology | MEDFORD, Mass., May 2, 2024 /PRNewswire/ -- YourBio Health, a Boston-based pioneer in remote, capillary whole blood collection technology, congratulates Myriad Genetics for having sold one million of its leading SneakPeek® Tests. Since 2021... |
27.02.2024 | Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered... | Highlights:
Full-year testing volume grew 35% year-over-year, or 18% ex-SneakPeek® volume.
Full-year 2023 revenue of $753 million, grew 11% year-over-year driven by Prenatal (30%, 15% ex-SneakPeek), Prolaris (21%), Pharmacogenomics (9%), an... |
03.05.2023 | Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point... | /EIN News/ -- Highlights:
First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.
In the first quarter:
Hereditary cancer test volumes grew 24% year-over... |
28.02.2023 | Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight... | /EIN News/ -- Highlights:
Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek® Early Gender DNA Test.
GeneSight, the com... |
09.02.2023 | Myriad Genetics to Participate in Upcoming Healthcare Conferences | /EIN News/ -- SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the upcoming healthcare conferences.
T... |
01.11.2022 | Gateway Genomics Joins Forces with Myriad Genetics to Further the Accessibility of Genetic Information to Consumers | This partnership is a commitment to offer a comprehensive suite of women’s health testing solutions before, during, and after pregnancy.
LA JOLLA, Calif. (PRWEB) November 01, 2022
Gateway Genomics Joins Forces with Myriad Genetics to Furthe... |
23.08.2022 | CLARIFIED PRECISION MEDICINE AND MYRIAD GENETICS PARTNER TO ADVANCE PERSONALIZED PATIENT CARE AND TREATMENT PLANS | Partnership creates new Molecular Tumor Board with peer-to-peer service to support interpreting results from molecular tests
Myriad Genetics, Inc. (NASDAQ:MYGN)
TAMPA, FL, UNITED STATES, August 23, 2022 /EINPresswire.com/ -- [TAMPA, FL, Aug... |
04.08.2022 | Myriad Genetics Reports Second Quarter Financial Results | Highlights:
Revenue of $179.3 million for the quarter ended June 30, 2022
Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially from the first quarter of 2022
Diluted GAAP earnings per share (EP... |
26.05.2022 | Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022 | SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meetin... |
05.05.2022 | Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022 | Highlights:
Revenue of $164.9 million for the quarter ended March 31, 2022
Excluding revenue from divested businesses, revenue increased 11% year-over-year
Diluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the ... |
24.02.2022 | Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives | Highlights:
Strong business performance despite COVID-19 headwinds
Revenue of $160.8 million in the fourth quarter and $690.6 million for the year ended Dec. 31, 2021, up 4% and 24%, respectively
Excluding revenue from divested businesses, ... |
02.11.2021 | Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans | Highlights:
Revenue of $167.3 million up 15% year-over-year. Excluding revenue from divested businesses, revenue increased 27% year-over-year
Diluted GAAP earnings per share (EPS) of $0.30 and adjusted EPS of $(0.02)
SALT LAKE CITY, Nov. 02... |
28.04.2021 | MYRIAD GENETICS, INC.
Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment | SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) -- In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression. Yet, mos... |
29.03.2021 | MYRIAD GENETICS, INC.
Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders | SALT LAKE CITY, March 29, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer. In this role, he will be responsible fo... |
02.03.2021 | Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services | SALT LAKE CITY, March 02, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a new strategic precision oncology collaboration with Intermountain Precision Genom... |
25.02.2021 | Slone Partners Places Mark Capone as Non-Executive Board Member at Abcam | “Mark Capone is a tremendously accomplished and respected leader in molecular diagnostics, biotechnology, and product development,” said Slone Partners President Tara Kochis-Stach.
SOUTH RIDING, Va. (PRWEB) February 25, 2021
Slone Partners,... |
23.02.2021 | Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan | Highlights:
Revenue of $154.6 million up 6% sequentially in quarter ended Dec. 31, 2020
GAAP Earnings per share (EPS) of ($0.59) and adjusted EPS of ($0.12)
Despite COVID-19 headwinds, total test volumes increase 7% sequentially with stable... |
18.02.2021 | Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives | SALT LAKE CITY, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new technology and healthcare leaders who recently joined the company as wel... |
12.02.2021 | New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer | SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris® test and it... |
11.02.2021 | Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences | SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sha... |
24.11.2020 | Mark your calendars for our virtual INVEST Precision Medicine conference, December 9-11 | What Does the Diagnostics Landscape Look Like?
Diagnostics is joined at the hip with precision medicine. The rapidly evolving field has led to the ability to quickly, reliably and affordably sequence an individual’s entire genome and the de... |
14.07.2019 | Kroger partners with Myriad Genetics on genetic testing pilot | A study published earlier this year in the Journal of Psychiatric Research found that the GeneSight test was able to drive improvements in remission among depression patients who have failed at least one medication trial.
“Depression is a l... |
22.06.2019 | Pioneering genetic-testing company Myriad's biggest up-and-coming product could be at risk after scientists raised major questions | Advertisement
Genetic tests like one offered by Myriad Genetics claim to analyze a patient's DNA and point them to the best depression drug for them.
Myriad's test is called GeneSight and costs $2,000. It's covered for seniors on the govern... |
12.09.2018 | Study cracks open the secrets of the cancer-causing BRCA1 gene | Lawsuits didn’t do it, public shaming didn’t do it, patients and doctors banding together to “free the data” couldn’t do it: For 22 years Myriad Genetics, one of the oldest genetic testing companies, has refused to make public its proprieta... |
28.05.2018 | Myriad Genetics acquires genetic testing startup Counsyl for $375 million | The demands for genetic testing continue to rise. The global genetic testing market is anticipated to grow from $5.05 billion in 2017 to $11.86 billion by 2026. As of 2018, there are at least 120 genetic startups, according to publicly avai... |
22.05.2017 | Color secures widespread coverage for its hereditary cancer test | Announced Monday, the coverage comes through a new partnership with some of the largest payers in the U.S. The deal includes mega-insurers such as United Healthcare, as well as regional players like Blue Shield of California. Combined, the ... |
07.08.2016 | Myriad Genetics to Acquire Assurex Health | Myriad Genetics, Inc. (NASDAQ:MYGN), a molecular diagnostics and personalized medicine company, is to acquire Assurex Health, a provider of genetic testing solutions for psychotropic medicine selection.
The deal amounted to $225m upfront wi... |
27.03.2015 | Genomics Needs A Killer App | Mark Kaganovich Contributor
Mark Kaganovich is the CEO and cofounder of SolveBio . Follow him on twitter at @markkaganovich.
More posts by this contributor
Is enterprise genomics good enough yet?
Genomics is an incredible technology for new... |
23.12.2013 | 5 memorable moments that shaped health-tech in 2013 | 2013 was a remarkable year for digital health.
Health technology was one of the hottest sectors in Silicon Valley in 2013, with investors pouring $1.5 billion into the space by the end of the third quarter. Entrepreneurs jumped into health ... |
18.07.2013 | Will the Supreme Court’s decision on “gene patents” stifle medical innovation? | The Supreme Court’s ruling did not hand a clear victory to either party.
By Nicole King, PhD
The recent ruling by the U.S. Supreme Court brought Association for Molecular Pathology v. Myriad Genetics back to the headlines, with interest bei... |
14.05.2013 | Genetic testing, cancer and preventive surgery: Not just in breast cancer | Angeline Jolie’s disclosure of her double mastectomy has drawn the mainstream media’s attention to genetic testing, a recent medical advancement with huge, albeit challenging, implications.
Many experts predict that genetic testing is on it... |
29.04.2013 | RainDance Technolgies raises $20M to grow market for DNA sequencing tools | The company’s core customers are genetic laboratories carrying out research for personalized drug development and diagnostics. Although it has traditionally been a laborious process to test different regions of the human genome, the company... |
29.04.2013 | Raindance Technologies gets $20M to improve genetic testing, signs deal with Myriad Genetics | Raindance Technologies has closed a $20 million fifth round of funding with strategic investment from Myriad Genetics, the biotech company at the center of this month’s debate about we should be able to patent human genes.
Myriad’s involvem... |
15.04.2013 | Should human genes be patented? Navigenics founder says ‘absolutely not’ | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Should human genes be patented? The Supreme Court... |
15.04.2013 | Should human genes be patented? Navigenics founder says ‘absolutely not’ | Should human genes be patented? The Supreme Court is weighing in today in a landmark case, Association for Molecular Pathology v. Myriad Genetics, Inc., 12-398., that will have an enormous impact on the future of science, technology, and me... |
08.08.2012 | Cancer diagnostics company using genomics analysis raising $1.3 million | Location: Pittsburgh, Pennsylvania.
Solution/product: The biotechnology company uses genomics analysis to detect cancer. PathFinder TG uses molecular analysis of mutations in genomic DNA to provide a more accurate reading in cases where tra... |
10.09.2011 | Crescendo Bioscience Raises $56M | Crescendo Bioscience, a South San Francisco, CA-based molecular diagnostics company developing quantitative biomarker tests for rheumatoid arthritis and other inflammatory diseases, has completed a $31m Series C equity financing and entered... |
07.11.2007 | Navigenics finally offers you a peek at your genome — except not really, and not yet | (UPDATED: See below.)
So at long last, one of the personal-genomics companies we’ve been writing about since May has finally launched its service. Navigenics, the Redwood City, Calif., startup that promises users a “personalized genetics an... |
- | Color secures widespread coverage for its hereditary cancer test | Color’s insurance provider portal
Is hereditary cancer screening really worth it for the general population? Increasingly, the answer is ‘yes.’
As proof, look no further than Burlingame, California-based Color. Starting June 15, the 2013 st... |
- | RainDance Technolgies raises $20M to grow market for DNA sequencing tools | It seems like many of the ongoing developments in genetic research share one thing in common: the need for speed. RainDance Technologies, a life science company with DNA sequencing tools to aid research and development for personalized ther... |
- | Cancer diagnostics company using genomics analysis raising $1.3 million | Company name: RedPath Integrated Pathology.
Industry: Cancer diagnostics.
Location: Pittsburgh, Pennsylvania.
Solution/product: The biotechnology company uses genomics analysis to detect cancer. PathFinder TG uses molecular analysis of muta... |
- | Mark your calendars for our virtual INVEST Precision Medicine conference, December 9-11 | The vision of precision medicine is to enable doctors, researchers and others to more accurately predict and prescribe appropriate treatments based on individuals genetic profile and other factors. Our virtual MedCity INVEST Precision Medic... |
- | Kroger partners with Myriad Genetics on genetic testing pilot | Kroger Health, the healthcare arm of the grocery store chain, has teamed up with genetic testing company Myriad Genetics, on a pilot meant to help employees receive personalized treatments for depression.
The Cincinnati, Ohio-based company ... |
- | Women deserve more data-driven answers about breast cancer risk; it’s up to us | Approximately 13% of women in the United States will develop breast cancer over the course of their lifetime1. That’s one in eight women.
Further, breast cancer does not target all women equally. For example, Black women have a higher chanc... |
- | Genetic testing, cancer and preventive surgery: Not just in breast cancer | Angeline Jolie’s disclosure of her double mastectomy has drawn the mainstream media’s attention to genetic testing, a recent medical advancement with huge, albeit challenging, implications.
Many experts predict that genetic testing is on it... |